In addition, we used oclacitinib, an oral JAK inhibitor registered for the treatment of canine allergic dermatitis, to successfully ameliorate intradermal IL-31-induced pruritic behaviors in this study and validate the model. This evidence concerns the gene IL31 and atopic eczema.